At a campaign event last week for GOP presidential candidate Donald Trump and his running mate JD Vance, attendees waved placards emblazoned with a slogan that is also used by a notorious white ...

As one of the leading Japanese pharmaceutical companies with headquarters in Europe, Daiichi Sankyo aims to revolutionize treatment standards. Daiichi Sankyo, a pharmaceutical group boasting over ...

The decommissioning process for the Fukushima Daiichi site and surroundings is scheduled to be completed by 2051. It will require many innovations, and careful planning. Here are some of the details ...

As Daiichi Sankyo and AstraZeneca’s metastatic breast cancer drug Enhertu picks up more label expansions, the companies are targeting patients directly for the first time in messaging efforts. Daiichi ...

Two years after AstraZeneca splashed out $1 billion upfront for rights to Daiichi Sankyo's TROP2-targeting antibody-drug conjugate DS-1062, the drug has generate promising results in advanced non ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Daiichi Sankyo Co. will seek to maintain its edge over competitors in precision cancer therapies, by pushing ahead with clinical trials of drug candidates being developed using new technology, a ...

AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate (ADC) has again failed to improve overall survival (OS) in a phase 3 trial. The latest miss happened in breast cancer ...

AstraZeneca and Daiichi Sankyo's Dato-DXd failed to improve survival in a breast cancer study. Gilead Sciences' Kite will bow out of its China joint venture with Fosun Pharma. Korea's Yuhan ended ...

MSD and Daiichi Sankyo have revealed some of the clinical data that prompted them to start pivotal testing of ifinatamab deruxtecan (I-DXd) in patients with previously treated, extensive-stage ...

Merck and Daiichi Sankyo's HER3 antibody-drug conjugate reported a positive phase 3 result in EGFR-mutated lung cancer. Merck and Eisai's Keytruda-Lenvima combo delivered a win in liver cancer.